Evidence map›Paper›PMID 33574048›Full record

ReviewMolecular pharmacology2021

Phosphoproteomic Analysis as an Approach for Understanding Molecular Mechanisms of cAMP-Dependent Actions.

Joseph A Beavo, Martin Golkowski, Masami Shimizu-Albergine, Michael-Claude Beltejar, Karin E Bornfeldt, Shao-En Ong

Abstract readReview
In one paragraph

Review in Molecular pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joseph A BeavoDepartments of Pharmacology and Medicine (J.A.B., M.G., M.S.-A., M.-C.B., S.-E.O.), and Division of Metabolism, Endocrinology and Nutrition (K.E.B.), University of Washington, Seattle, Washington beavo@uw.edu.
Martin GolkowskiDepartments of Pharmacology and Medicine (J.A.B., M.G., M.S.-A., M.-C.B., S.-E.O.), and Division of Metabolism, Endocrinology and Nutrition (K.E.B.), University of Washington, Seattle, Washington.
Masami Shimizu-AlbergineDepartments of Pharmacology and Medicine (J.A.B., M.G., M.S.-A., M.-C.B., S.-E.O.), and Division of Metabolism, Endocrinology and Nutrition (K.E.B.), University of Washington, Seattle, Washington.
Michael-Claude BeltejarDepartments of Pharmacology and Medicine (J.A.B., M.G., M.S.-A., M.-C.B., S.-E.O.), and Division of Metabolism, Endocrinology and Nutrition (K.E.B.), University of Washington, Seattle, Washington.
Karin E BornfeldtDepartments of Pharmacology and Medicine (J.A.B., M.G., M.S.-A., M.-C.B., S.-E.O.), and Division of Metabolism, Endocrinology and Nutrition (K.E.B.), University of Washington, Seattle, Washington.
Shao-En OngDepartments of Pharmacology and Medicine (J.A.B., M.G., M.S.-A., M.-C.B., S.-E.O.), and Division of Metabolism, Endocrinology and Nutrition (K.E.B.), University of Washington, Seattle, Washington.

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Identifying new strategies for prevention of cardiovascular complications of diabetesR35HL150754 · NHLBI · UNIVERSITY OF WASHINGTON · PI BORNFELDT, KARIN E · 2020 to 2025
$6.2M
New Molecular Probes For Protein KinasesR01GM086858 · NIGMS · UNIVERSITY OF WASHINGTON · PI MALY, DUSTIN J · 2008 to 2025
$5.5M
Regulation of Cellular Functions by Cyclic Nucleotide Phosphodiesterase 8R01GM083926 · NIGMS · UNIVERSITY OF WASHINGTON · PI BEAVO, JOSEPH A · 2008 to 2015
$3.0M
Supplement to DEFINING PATHWAY-SPECIFIC KINASE SIGNALING MODULES WITH PROTEOMICSR01GM129090 · NIGMS · UNIVERSITY OF WASHINGTON · PI ONG, SHAO-EN · 2019 to 2022
$1.7M
Characterizing Muscle Regulatory Elements with Mass Spectrometry-Based ProteomicsR01AR065459 · NIAMS · UNIVERSITY OF WASHINGTON · PI ONG, SHAO-EN · 2013 to 2017
$1.6M
Kinase Profiling with Quantititative ChemoproteomicsR21CA177402 · NCI · UNIVERSITY OF WASHINGTON · PI MALY, DUSTIN J, ONG, SHAO-EN · 2013 to 2015
$665k
Frizzled2 Signaling in Metastatic CancersK22CA201229 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI GUJRAL, TARAN SINGH · 2016 to 2018
$562k
Target identification by small-molecule labeling in live cellsR21EB018384 · NIBIB · UNIVERSITY OF WASHINGTON · PI MALY, DUSTIN J, ONG, SHAO-EN · 2014 to 2015
$425k
NCI NIH HHS K22 CA201229NCI NIH HHS R21 CA177402NHLBI NIH HHS R35 HL150754NIAMS NIH HHS R01 AR065459NIBIB NIH HHS R21 EB018384NIDDK NIH HHS P30 DK017047NIGMS NIH HHS R01 GM083926NIGMS NIH HHS R01 GM086858NIGMS NIH HHS R01 GM129090
6 · The paper itself

Abstract

In recent years, highly sensitive mass spectrometry-based phosphoproteomic analysis is beginning to be applied to identification of protein kinase substrates altered downstream of increased cAMP. Such studies identify a very large number of phosphorylation sites regulated in response to increased cAMP. Therefore, we now are tasked with the challenge of determining how many of these altered phosphorylation sites are relevant to regulation of function in the cell. This minireview describes the use of phosphoproteomic analysis to monitor the effects of cyclic nucleotide phosphodiesterase (PDE) inhibitors on cAMP-dependent phosphorylation events. More specifically, it describes two examples of this approach carried out in the authors' laboratories using the selective PDE inhibitor approach. After a short discussion of several likely conclusions suggested by these analyses of cAMP function in steroid hormone-producing cells and also in T-cells, it expands into a discussion about some newer and more speculative interpretations of the data. These include the idea that multiple phosphorylation sites and not a single rate-limiting step likely regulate these and, by analogy, many other cAMP-dependent pathways. In addition, the idea that meaningful regulation requires a high stoichiometry of phosphorylation to be important is discussed and suggested to be untrue in many instances. These new interpretations have important implications for drug design, especially for targeting pathway agonists. SIGNIFICANCE STATEMENT: Phosphoproteomic analyses identify thousands of altered phosphorylation sites upon drug treatment, providing many possible regulatory targets but also highlighting questions about which phosphosites are functionally important. These data imply that multistep processes are regulated by phosphorylation at not one but rather many sites. Most previous studies assumed a single step or very few rate-limiting steps were changed by phosphorylation. This concept should be changed. Previous interpretations also assumed substoichiometric phosphorylation was not of regulatory importance. This assumption also should be changed.

Indexed as

AnimalsCyclic AMPHumansPhosphorylationProteomeProteomicsSignal TransductionCyclic AMPProteome

Identifiers

PMID33574048
PMCPMC8058506

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.